Sign in

CIK 0001674416

  • Large accelerated filer

CRISPR Therapeutics AG

Sign in to watch
Ticker
CRSP
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
Switzerland
Entity type
Operating
EIN
473173478
Phone
+1 617-315-4600
Business address
BAARERSTRASSE 14, ZUG, Switzerland
Former names
CRISPR Therapeutics AG
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$4,881,673
in 7 filings, $1.5M under 10b5-1 plans

Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2017-06-22 EMSTER KURT VON Director Sale −1,527 $16.21 $25K 2,600,287
2017-06-22 Novak Rodger Chief Executive Officer Exercise or conversion +10,825 $1.81 $20K 1,225,830
2017-06-22 Novak Rodger Chief Executive Officer Sale −10,825 $15.37 $166K 1,215,005
2017-06-22 Novak Rodger Chief Executive Officer Exercise or conversion · Stock Options (Right to Buy) −10,825 68,093
2017-06-21 Novak Rodger Chief Executive Officer Exercise or conversion +11,578 $1.81 $21K 1,266,583
2017-06-21 Novak Rodger Chief Executive Officer Sale −11,578 $15.02 $174K 1,215,005
2017-06-21 Novak Rodger Chief Executive Officer Exercise or conversion · Stock Options (Right to Buy) −11,578 78,918
2017-06-20 Novak Rodger Chief Executive Officer Exercise or conversion +3,252 $1.81 $6K 1,218,257
2017-06-20 Novak Rodger Chief Executive Officer Sale −3,252 $15.00 $49K 1,215,005
2017-06-20 Novak Rodger Chief Executive Officer Exercise or conversion · Stock Options (Right to Buy) −3,252 90,496
2017-06-19 Novak Rodger Chief Executive Officer Exercise or conversion +15,392 $1.81 $28K 1,230,397
2017-06-19 Novak Rodger Chief Executive Officer Sale −15,392 $15.00 $231K 1,215,005
2017-06-19 Novak Rodger Chief Executive Officer Exercise or conversion · Stock Options (Right to Buy) −15,392 93,748
2017-06-15 Dylan-Hyde Tyler Chief Legal Officer Grant or award · Stock Option (Right to Buy) +65,000 65,000
2017-06-15 Novak Rodger Chief Executive Officer Grant or award · Stock Options (Right to Buy) +270,000 270,000
2017-06-15 Subramanian Kala Grant or award · Stock Options (Right to Buy) +85,000 85,000
2017-06-09 Novak Rodger Chief Executive Officer Exercise or conversion +1,100 $1.81 $2K 1,216,105
2017-06-09 Novak Rodger Chief Executive Officer Sale −1,100 $15.08 $17K 1,215,005
2017-06-09 Novak Rodger Chief Executive Officer Exercise or conversion · Stock Options (Right to Buy) −1,100 109,140
2017-06-08 Novak Rodger Chief Executive Officer Exercise or conversion +4,203 $1.81 $8K 1,219,208

Page 63 of 74 · 1,471 trades